(firstQuint)Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study.

 This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial.

 Patients will return to the study center approximately every 3 months for safety evaluations including physical exam, blood and urine tests.

.

 Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study@highlight

This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial.

